PERSPECTIVE3-5 min to read

Obesity is a growing problem

As global obesity rates rise, so too is expected spending on obesity-related healthcare.

15/02/2024
Obesity

Weight loss drugs have been the biggest story in the pharmaceutical sector over the past year. These treatments regulate blood sugar, commonly called glucagon-like peptide 1 (GLP-1) agonists. Ozempic is one of the most well-known brands, with many celebrities admitting to using it, from Elon Musk to Amy Schumer. Two companies at the forefront of developing these treatments are Eli Lilly and Novo Nordisk. It is estimated that together they make up 90% of the obesity treatment market.

Global obesity rates are steadily rising

Obesity rates globally and across select countries (%)

610561_CC_J23013_magazine_dialogue_january-2024_Obesity-is-a-growing-problem_p14

Source: World Health Organization (WHO). Data as of 2016 (published in 2021).

Of the 537 million diabetics worldwide, just 15% are in good control of their condition. Meanwhile, just 2% of the 764 million with obesity are treated medically.

Both Eli Lilly and Novo Nordisk are highly cash generative businesses, with large and growing research and development budgets, which should cement their market leadership. These innovations are causing a paradigm shift in the way that obesity and its related diseases are treated, with doctors offering more weight-centric treatment plans in the first instance.

Expected obesity-related healthcare spending up to 2050

610561_CC_J23013_magazine_dialogue_january-2024_Chart-1-P14_v2

Source: World Health Organization (WHO), Organization for Economic Co-operation and Development (OECD).

The opportunities stretch beyond glycaemic control and weight loss, with huge patient populations across related diseases all in need of treatments.

Existing global patient populations across potential treatment areas for GLP-1 drugs

610561_CC_J23013_magazine_dialogue_january-2024_Chart-2-P14

Source: Capital Group, Centers for Disease Control and Prevention (CDC), World Health Organization (WHO), World Obesity Federation.

Issued in the Channel Islands by Cazenove Capital which is part of the Schroders Group and is a trading name of Schroders (C.I.) Limited, licensed and regulated by the Guernsey Financial Services Commission for banking and investment business; and regulated by the Jersey Financial Services Commission. Nothing in this document should be deemed to constitute the provision of financial, investment or other professional advice in any way. Past performance is not a guide to future performance. The value of an investment and the income from it may go down as well as up and investors may not get back the amount originally invested. This document may include forward-looking statements that are based upon our current opinions, expectations and projections. We undertake no obligation to update or revise any forward-looking statements. Actual results could differ materially from those anticipated in the forward-looking statements. All data contained within this document is sourced from Cazenove Capital unless otherwise stated.

 

Topics

Cazenove Capital is a trading name of Schroders (C.I.) Ltd which is licensed under the Banking Supervision (Bailiwick of Guernsey) Law 2020 and the Protection of Investors (Bailiwick of Guernsey) Law 2020, as amended in the conduct of banking and investment business. Registered address at Regency Court, Glategny Esplanade, St. Peter Port, Guernsey GY1 3UF, (No.24546) . Schroders (C.I.) Limited, Jersey Branch is regulated by the Jersey Financial Services Commission in the conduct of investment business. Registered address at IFC1, Esplanade, St Helier, Jersey, JE2 3BX, (No.31076).

The value of your investments and the income received from them can fall as well as rise. You may not get back the amount you invested.